Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Breast cancer advance wins $7.4m US award for Austrian Research Institute

22.10.2012
A new approach to possible future prevention of breast cancer and slowing the spread of tumours has won Austrian researcher Josef Penninger, director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, a $7.4 million innovator’s award to continue his research, from the USA’s Congressionally Directed Medical Research Program.

The innovator’s award recognises Josef Penninger’s work in identifying a key molecular pathway how hormone replacement therapies and contraceptive pills can lead to breast cancer. His team provided the first genetic proof that a protein called RANKL is the master regulator of bone loss, which has contributed to the development of a novel drug already approved for the treatment of osteoporosis and skeletal related events in multiple cancers.

He was also the first to discover that RANKL not only regulates bone loss but is absolutely essential to enable sex hormone driven lactation in pregnant females, a finding that could explain further the connection between sex hormones and bone loss. Based on these groundbreaking findings, Penninger’s group went on to show that RANKL is indeed a missing link between sex hormones, in particular the sex hormone progesterone, and breast cancer, leading to the hypothesis that RANKL is a key driver of breast cancer initiation.

In addition, Penninger’s group has developed entirely novel genetics tools, so-called haploid stem cells, to quickly assess the function of specific genes that cause breast cancer and help tumours to spread. “This is the next step in the post genome era of cancer”, says Prof Josef Penninger. “We will use our new technologies to rapidly check the function of hundreds or even thousands of human breast cancer gene candidates”. The Austrian researchers expect to verify new breast cancer pathways, which they hope will quickly lead to a major impact in preventing and treating the disease.

Supported by the $7.4 million award, Josef Penninger intends to further use this knowledge to develop a new diagnostic method that helps in making predictions concerning the chances that any patient will develop breast cancer. At risk patients will then be able to start preventative treatment using the existing RANK ligand-blocking medicines. Josef Penninger adds: “If our experimental data could be extrapolated to humans, which is what we strongly believe, then we might have an entirely novel way of early breast cancer detection and, since RANKL inhibition is already used in patients, we even would have a medicine within immediate reach that could be used to possibly prevent the disease in those women at high risk”.

ENDS

IMBA:
The Institute of Molecular Biotechnology (IMBA) combines fundamental and applied research in the field of biomedicine. Interdisciplinary research groups address functional genetic questions, particularly those related to the origin of disease. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading organization promoting non-university academic basic research in Austria. Earlier this year IMBA was voted as second to top international workplace for postdoctoral researchers, by readers of the US based and online life sciences magazine, The Scientist.
Contact:
Evelyn Devuyst
IMBA Communications
Phone: +43 1 79730 3626
evelyn.devuyst@imba.oeaw.ac.at
References:
Schramek et al. (2010). Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 468(7320):98-102
IMBA press release from 2010: „Researchers find how HRT and the Pill can lead to breast cancer and suggest possible treatment“

http://www.imba.oeaw.ac.at/uploads/media/presstext100929-breast_cancer.pdf

Innovator Award:
Josef Penninger was awarded with the Innovator Award for his project “Novel Approaches to Breast Cancer Prevention and Inhibition of Metastases” (contract number W81XWH-12-1-0093) through the US Department of Defense. Congressionally Directed Medical Research Program: http://cdmrp.army.mil/bcrp/

Evelyn Devuyst | idw
Further information:
http://www.oeaw.ac.at

More articles from Awards Funding:

nachricht The quest for the oldest ice on Earth
14.11.2016 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung

nachricht Empa Innovation Award for new flame retardant
09.11.2016 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Awards Funding >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Will Earth still exist 5 billion years from now?

08.12.2016 | Physics and Astronomy

Oxygen can wake up dormant bacteria for antibiotic attacks

08.12.2016 | Health and Medicine

Newly discovered bacteria-binding protein in the intestine

08.12.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>